Drug Discovery, High- Throughput, High-Content Screening
Associate Adjunct Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
Dr. Siqueira-Neto’s research has focused on development and implementation of screening assays to identify active molecules and natural products against parasites causing neglected tropical diseases.
B.S. in Biological Sciences (2003) University of Campinas, SP - Brazil; Ph.D. in Molecular Genetics (2007) University of Campinas, SP - Brazil; Postdoctoral Fellow (2007-2009) Institut Pasteur Korea - South Korea.
Awards and Honors:
CAPES Doctorate International Internship Scholarship (2005); DNDi Partnership of the Year, New Delhi, India (2010).
Team Leader and Drug Discovery Program Coordinator at Institut Pasteur Korea (2009-2012); Kinetoplastida Core Director from the Center for Discovery and Innovation in Parasitic Diseases, UCSF & UCSD (2013-present); Assistant Adjunct Professor at Skaggs School of Pharmacy and Pharmaceutical Sciences, UCSD (2014-present).
- Development of the first High-Content Screening for Leishmania and Trypanosoma cruzi
- Dossin et al. (2008) Automated nuclear analysis of Leishmania major telomeric clusters reveals changes in their organization during the parasite's life cycle. PLoS One. 3(6):e2313.
- Siqueira-Neto et al. (2010) Antileishmanial high- throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis. 4(5):e675.
- Freitas-Junior et al. (2012) Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?International Journal for Parasitology: Drugs and Drug Resistance. 2:11–19.
- Siqueira-Neto et al. (2012) An Image-based High- Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages. PLoS Negl Trop Dis. (6):e1671.
- Moon et al. (2014) An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite Trypanosoma cruzi. PLoS One. 9(2):e87188.
- Calvet et al. (2014) 4-aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency. J Med Chem. 2014 Aug 7. [Epub ahead of print]
- Drug discovery for neglected tropical diseases
- High-Throughput, High-Content Screening assay development